Business Context and Reporting Period
Company: Cuprina Holdings (Cayman) Limited (Ticker: CUPR)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: A Singapore-based biomedical company developing and commercializing innovative products for chronic wound management (Maggot Debridement Therapy) and cosmeceuticals. The company operates primarily through its Singapore subsidiary, Cuprina Pte. Ltd.
Recent Capital Event: Completed an Initial Public Offering (IPO) on April 11, 2025, raising approximately US$10.85 million in net proceeds (including over-allotment).
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (S$) | 2024 (US$) | 2023 (S$) |
|---|---|---|---|
| Revenue | 48,321 | 35,522 | 100,773 |
| Cost of Revenues | 51,345 | 37,745 | 64,168 |
| Gross Profit / (Loss) | (3,024) | (2,223) | 36,605 |
| Gross Margin | (6.3%) | (6.3%) | 36.3% |
| Net Loss | (1,560,535) | (1,147,199) | (1,119,555) |
| Cash and Cash Equivalents | 116,472 | 85,622 | 35,263 |
| Net Current Liabilities | (4,384,999) | (3,223,552) | (2,990,424) |
| Bank Loans (Total) | 218,978 | 160,978 | 64,250 |
Note: US$ amounts are translated at the year-end rate of 0.7351. The company reported a gross loss in 2024 due to fixed costs exceeding revenue.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 52.0% to S$48,321 from S$100,773 in 2023. This was primarily driven by a reduction in MEDIFLY product sales (maggot-based wound care) in Singapore and Hong Kong, with patient numbers dropping from 135 to 78.
- Gross Margin Compression: The company shifted from a 36.3% gross profit margin in 2023 to a 6.3% gross loss margin in 2024. Fixed costs (production staff, rental, depreciation) remained relatively stable despite the revenue drop.
- Operating Expenses Increase: Total operating expenses rose 48.6% to S$1.64 million. This increase was driven by higher professional fees (audit, IPO-related), payroll increases, and R&D costs.
- Related Party Debt: Amounts due to related parties (shareholders and beneficial owners) increased significantly to S$5.63 million, primarily to finance working capital and R&D.
Guidance, Outlook, and Risks
Outlook and Strategy
- Product Pipeline: Developing bullfrog collagen sponge dressings and hydrogels, with FDA 510(k) submission expected in 2025 and commercial availability targeted for 2026. Also developing medical leech therapy products.
- Geographic Expansion: Strategic plans to expand into mainland China, the Middle East (GCC), and Southeast Asia through joint ventures and distribution partnerships.
- Liquidity: Management believes the IPO proceeds (US$10.85 million) combined with existing cash will be sufficient to meet operational needs for the next 12 months.
Key Risks and Contingencies
- Profitability: The company has a history of losses and an accumulated deficit of S$4.56 million. There is no assurance it will achieve or sustain profitability.
- Regulatory Approval: Future growth depends on obtaining FDA 510(k) clearance for MEDIFLY and pipeline products. Delays or denials would materially harm the business.
- Intellectual Property: The primary revenue-generating product (MEDIFLY) has no patent protection and relies on trade secrets, exposing the company to competition from equivalent products.
- Internal Controls: The company identified four material weaknesses in internal controls over financial reporting (entity-level controls, accounting resources, segregation of duties, and contract documentation) during the IPO audit process.
- Customer Concentration: The top five customers accounted for 71.2% of revenue in 2024, with the largest single customer representing 23.8%.
Investor Verification Checklist
- Going Concern Status: Verify the utilization of IPO proceeds and whether the company can bridge the gap between current cash burn and future revenue generation from pipeline products.
- Regulatory Timeline: Monitor the status of FDA 510(k) submissions for both MEDIFLY and bullfrog collagen products, as these are critical for US market entry and global regulatory alignment.
- Internal Control Remediation: Review subsequent filings for updates on the remediation of the four identified material weaknesses in internal controls.
- Related Party Transactions: Scrutinize the terms and repayment schedules of the S$5.6 million in debt owed to related parties and shareholders.
- Revenue Recovery: Assess whether the decline in MEDIFLY sales is a temporary fluctuation or a structural shift in market demand or hospital procurement policies.